Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) for the reporting period of June 29, 2015. The filing reports on the results of a special meeting of stockholders held on that date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
- Stockholder Meeting: 10,816,376 shares were present or represented by proxy out of 15,045,080 shares entitled to vote.
- Voting Outcome: Stockholders approved an amendment to the Restated Certificate of Incorporation authorizing a reverse stock split (ratio of 1-for-5 to 1-for-9) and a proportional decrease in authorized shares.
- Vote Breakdown: 8,437,273 votes FOR, 2,101,203 votes AGAINST, and 277,900 votes ABSTAIN.
Outlook, Management Commentary, and Risks
Management reported that since filing the definitive proxy statement on June 8, 2015, the company's stock price has returned to trading over $1.00. Consequently, the company now meets the requirements to remain listed on NASDAQ, and the exchange has determined the stock is no longer subject to delisting.
Reverse Split Status: Although the reverse stock split was approved by stockholders, management stated they will not implement it at this time because it is no longer necessary to maintain the NASDAQ listing. The company retains the authority to implement the reverse split at any time prior to June 29, 2016.
Key Facts for Investor Verification
- Verify the current stock price to confirm it remains above the $1.00 threshold required for NASDAQ listing.
- Monitor future announcements to determine if the board decides to exercise its authority to implement the approved reverse stock split before June 29, 2016.
- Confirm the company's continued compliance with NASDAQ listing standards in subsequent filings.